FTY720 (fingolimod) for relapsing multiple sclerosis

  title={FTY720 (fingolimod) for relapsing multiple sclerosis},
  author={Alejandro Horga and Xavier Montalban},
  journal={Expert Review of Neurotherapeutics},
  pages={699 - 714}
FTY720 (fingolimod) is a structural analogue of sphingosine, an endogenous lysophospholipid, which targets sphingosine-1-phosphate receptors after biotransformation to FTY720-phosphate. The immunomodulatory properties of this agent are mainly related to its ability to entrap lymphocytes in secondary lymphoid organs, reducing their availability for cell-mediated immune responses. Emerging evidence suggests that FTY720 also exerts direct actions on glial and precursor cells of the CNS which may… 

Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis

Fingolimod reduces relapses more effectively than intramuscular interferon β1a and delays disability progression and may target not only inflammation but potentially also neurodegeneration.

Fingolimod for relapsing multiple sclerosis: an update

Importance of the field: Multiple sclerosis (MS) is the most common inflammatory demyelinating disease of the CNS. There is a large unmet need for new disease-modifying therapies with improved

Acute Anterior Uveitis in a Patient Taking Fingolimod (FTY720) for Multiple Sclerosis

The case of a 34-year-old male with relapsing-remitting multiple sclerosis, who developed acute anterior uveitis on day 5 of fingolimod treatment, is reported.

Modulators of the Sphingosine 1-phosphate receptor 1.

Emerging multiple sclerosis oral therapies

Fingolimod, a novel immunosuppressant, significantly lowered annual relapse rates in phase II/III trials and teriflunomide, an immunomodulator, significantly reduced MRI lesion activity and reduced annual relapse Rates in a phase II trial.

The Role of MicroRNAs in Repair Processes in Multiple Sclerosis

The role of miRNAs in remyelination in the different cell types that contribute to MS is examined, focusing on key miRNA that have a central role in mediating the repair process, along with several more that play either secondary or inhibitory roles in one or more aspects.

High-Resolution Expression Profiling of Peripheral Blood CD8+ Cells in Patients with Multiple Sclerosis Displays Fingolimod-Induced Immune Cell Redistribution

The fingolimod-induced transcriptome changes reflect a shift in the proportions of CD8+ T cell subsets, with CCR7- effector memory T cells being relatively increased in frequency in the blood of fingolIMod-treated patients and genes involved in T cell activation and lymphocyte cytotoxicity were increased in expression.

Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists

This review will focus on SM drugs approved and under development, including JAK inhibitors and S1PR agonists and their mechanism of action.



FTY720 (fingolimod) in renal transplantation

FTY is highly effective in prolonging allograft survival in preclinical models of transplantation and in experimental models of autoimmune diseases, and is the first in a new class of drugs called sphingosine 1‐phosphate receptor (S1P‐R) modulators.

Current perspectives on FTY720

Recently, the surprising results of two sister Phase III studies in de novo renal transplant patients, as well as a Phase II study in patients with relapsing multiple sclerosis, were published, and their implications for the future of sphingosine-1 receptor modulation are discussed.

The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors*

The results suggest that FTY720, after phosphorylation, acts through sphingosine 1-phosphate signaling pathways to modulate chemotactic responses and lymphocyte trafficking.

The Immunomodulator FTY720 Has a Direct Cytoprotective Effect in Oligodendrocyte Progenitors

Observations suggest that in addition to its immunosuppressive functions, FTY720 could also have a beneficial effect in MS by direct action on OLG progenitors, and raises the question of whether MS therapies with FTY 720 should include the use of differentiation-enhancing factors such as NT-3.

Oral fingolimod (FTY720) for relapsing multiple sclerosis.

In this proof-of-concept study, fingolimod reduced the number of lesions detected on MRI and clinical disease activity in patients with multiple sclerosis and both measures decreased in patients who switched from placebo to fingolIMod.

FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis

Gene deletion and reverse pharmacology studies have shown that FTY720 acts at S1P1 receptors on lymphocytes and the endothelium, thereby inhibiting the egress of T- and B cells from secondary lymphoid organs into the blood and their recirculation to inflamed tissues.

Brain Penetration of the Oral Immunomodulatory Drug FTY720 and Its Phosphorylation in the Central Nervous System during Experimental Autoimmune Encephalomyelitis: Consequences for Mode of Action in Multiple Sclerosis

It is shown that FTY720 localizes to the CNS white matter, preferentially along myelin sheaths, and is likely due to a culmination of mechanisms involving reduction of autoreactive T cells, neuroprotective influence of FTY 720-P in the CNS, and inhibition of inflammatory mediators in the brain.